RevenueNet IncomeP/EP/SEBITDividendStocksMarket capitalizationDebtLiabilitiesEquityAAQSEmployeesROEROAROCE
Onconova Therapeutics Stock

Onconova Therapeutics P/S 2024

Onconova Therapeutics P/S

1.18

Ticker

ONTX

ISIN

US68232V4059

WKN

A2N6RH

As of Nov 7, 2024, Onconova Therapeutics's P/S ratio stood at 1.18, a -56.93% change from the 2.74 P/S ratio recorded in the previous year.

The Onconova Therapeutics P/S history

Onconova Therapeutics Aktienanalyse

What does Onconova Therapeutics do?

Onconova Therapeutics Inc. is a biopharmaceutical company focused on the development of drugs and therapies for the treatment of cancer. The company was founded in Pennsylvania in 1998 and is headquartered in Newtown, Pennsylvania. In 2013, the company went public and was listed on the NASDAQ. The history of Onconova Therapeutics began with the discovery of a new class of compounds known as precursor nucleotide analogs. These compounds were developed in collaboration with the National Cancer Institute (NCI) and showed promising results in cancer treatment. Onconova aims to develop innovative cancer therapies that allow for targeted attack on cancer cells without damaging healthy cells in the body. The company's research and development efforts focus on the discovery and development of new compounds and therapy approaches, as well as improving existing cancer treatments. The business model of Onconova Therapeutics is centered around building long-term partnerships with leading pharmaceutical companies, academic institutions, and research facilities. The company works closely with these partners to develop innovative therapies and drugs that meet the needs of cancer patients. Onconova has divided its product development into multiple areas to investigate the potential of its compounds in various therapy areas. The two main areas of focus for the company are myeloproliferative neoplasms (MPN) and oncology. Myeloproliferative neoplasms are a group of blood cancers that affect the bone marrow. Onconova Therapeutics has developed a promising class of compounds known as selective oral inhibitors (SOIs) that target the main drivers of MPNs and have shown positive results in clinical trials. The oncology division of the company focuses on the development of compounds for the treatment of solid tumors. Onconova has developed a targeted cancer therapy that focuses on inhibiting WNT signaling. This approach aims to allow for selective attack on cancer cells without damaging healthy cells in the body. In addition to these two areas, the company is also working on the development of compounds for the treatment of advanced tumors, lung cancer, and other types of cancer. The main product of Onconova Therapeutics is Rigosertib. Rigosertib is a selective oral inhibitor (SOI) specifically developed for the treatment of myelodysplastic syndromes (MDS) and acute myeloid leukemia (AML). The drug is currently in the final phase III of testing by the FDA. In addition to Rigosertib, Onconova is conducting further clinical studies to investigate the effectiveness and safety of its cancer drugs. The company aims to develop innovative therapy options that help cancer patients overcome their disease and lead longer lives without the harmful effects of conventional cancer therapies. Overall, Onconova Therapeutics Inc. has a promising future as an innovative biopharmaceutical company. By continuing its research and development activities in multiple areas and developing new compounds and therapies, Onconova will continually contribute to improving the lives of cancer patients. Onconova Therapeutics ist eines der beliebtesten Unternehmen auf Eulerpool.com.

P/S Details

Decoding Onconova Therapeutics's P/S Ratio

Onconova Therapeutics's Price to Sales (P/S) Ratio is a crucial financial metric that measures the company's market valuation relative to its total sales revenue. It's calculated by dividing the company's market capitalization by its total sales over a specific period. A lower P/S ratio can indicate that the company is undervalued, while a higher ratio may suggest overvaluation.

Year-to-Year Comparison

Comparing Onconova Therapeutics's P/S ratio yearly provides insights into how the market perceives the company’s value relative to its sales. An increasing ratio over time can indicate growing investor confidence, while a decreasing trend might reflect concerns about the company’s revenue generation capabilities or market conditions.

Impact on Investments

The P/S ratio is instrumental for investors evaluating Onconova Therapeutics's stock. It offers insights into the company’s efficiency in generating sales and its market valuation. Investors use this ratio to compare similar companies within the same industry, aiding in selecting stocks that offer the best value for investment.

Interpreting P/S Ratio Fluctuations

Variations in Onconova Therapeutics’s P/S ratio can result from changes in the stock price, sales revenue, or both. Understanding these fluctuations is crucial for investors to evaluate the company’s current valuation and future growth potential, aligning their investment strategies accordingly.

Frequently Asked Questions about Onconova Therapeutics stock

What is the price-to-earnings ratio of Onconova Therapeutics?

The price-earnings ratio of Onconova Therapeutics is currently 1.18.

How has the price-earnings ratio of Onconova Therapeutics changed compared to last year?

The price-to-earnings ratio of Onconova Therapeutics has increased by -56.93% fallen (meaning "decreased" or "dropped") compared to last year.

What consequences does a high price-earnings ratio have for investors?

A high price-to-earnings ratio indicates that the company's stock is relatively expensive and investors may potentially achieve a lower return.

What does a low price-earnings ratio mean?

A low price-earnings ratio means that the company's stock is relatively cheap and investors may potentially achieve a higher return.

Is the price-earnings ratio of Onconova Therapeutics high compared to other companies?

Yes, the price-to-earnings ratio of Onconova Therapeutics is high compared to other companies.

How does an increase in the price-earnings ratio of Onconova Therapeutics affect the company?

An increase in the price-earnings ratio of Onconova Therapeutics would lead to a higher market capitalization of the company, which in turn would lead to a higher valuation of the company.

How does a reduction in the price-to-earnings ratio of Onconova Therapeutics affect the company?

A decrease in the price-earnings ratio of Onconova Therapeutics would result in a lower market capitalization of the company, which in turn would lead to a lower valuation of the company.

What are some factors that influence the price-earnings ratio of Onconova Therapeutics?

Some factors that influence the price-earnings ratio of Onconova Therapeutics are the company's growth, financial position, industry development, and the overall economic situation.

How much dividend does Onconova Therapeutics pay?

Over the past 12 months, Onconova Therapeutics paid a dividend of . This corresponds to a dividend yield of about . For the coming 12 months, Onconova Therapeutics is expected to pay a dividend of 0 USD.

What is the dividend yield of Onconova Therapeutics?

The current dividend yield of Onconova Therapeutics is .

When does Onconova Therapeutics pay dividends?

Onconova Therapeutics pays a quarterly dividend. This is distributed in the months of .

How secure is the dividend of Onconova Therapeutics?

Onconova Therapeutics paid dividends every year for the past 0 years.

What is the dividend of Onconova Therapeutics?

For the upcoming 12 months, dividends amounting to 0 USD are expected. This corresponds to a dividend yield of 0 %.

In which sector is Onconova Therapeutics located?

Onconova Therapeutics is assigned to the 'Health' sector.

Wann musste ich die Aktien von Onconova Therapeutics kaufen, um die vorherige Dividende zu erhalten?

To receive the latest dividend of Onconova Therapeutics from 11/7/2024 amounting to 0 USD, you needed to have the stock in your portfolio before the ex-date on 11/7/2024.

When did Onconova Therapeutics pay the last dividend?

The last dividend was paid out on 11/7/2024.

What was the dividend of Onconova Therapeutics in the year 2023?

In the year 2023, Onconova Therapeutics distributed 0 USD as dividends.

In which currency does Onconova Therapeutics pay out the dividend?

The dividends of Onconova Therapeutics are distributed in USD.

Stock savings plans offer an attractive way for investors to build wealth over the long term. One of the main advantages is the so-called cost-average effect: by regularly investing a fixed amount in stocks or stock funds, you automatically buy more shares when prices are low, and fewer when they are high. This can lead to a more favorable average price per share over time. In addition, stock savings plans allow small investors access to expensive stocks, as they can participate with small amounts. Regular investment also promotes a disciplined investment strategy and helps to avoid emotional decisions, such as impulsive buying or selling. Furthermore, investors benefit from the potential appreciation of the stocks as well as from dividend distributions, which can be reinvested, enhancing the compounding effect and thus the growth of the invested capital.

Andere Kennzahlen von Onconova Therapeutics

Our stock analysis for Onconova Therapeutics Revenue stock includes important financial indicators such as revenue, profit, P/E ratio, P/S ratio, EBIT, as well as information on dividends. We also assess aspects such as stocks, market capitalization, debt, equity, and liabilities of Onconova Therapeutics Revenue. If you are looking for more detailed information on these topics, we offer comprehensive analyses on our subpages.